In face of accumulated reports demonstrating that uptake of some cell-penetrating peptides occurs through previously described endocytic pathways, or is a consequence of cell fixation artifacts, we conducted a systematic analysis on the mechanism responsible for the cellular uptake of the S4 13 -PV karyophilic cell-penetrating peptide. The results reviewed here show that the S4 13 -PV peptide is able to very efficiently accumulate inside live cells in a rapid, non-toxic and dose-dependent manner, through a mechanism distinct from endocytosis. Comparative analysis of peptide uptake by mutant cells lacking heparan sulfate proteoglycans demonstrates that, although not mandatory, their presence at cell surface facilitates the cellular uptake of the S4 13 -PV peptide. Furthermore, we demonstrate that upon interaction with lipid vesicles, the S4 13 -PV peptide undergoes significant conformational changes that are consistent with the formation of helical structures. Such conformational changes occur concomitantly with a penetration of the peptide into the lipid bilayer, strongly suggesting that the resulting helical structures are crucial for the non-endocytic cellular uptake of the S4 13 -PV peptide. Overall, our data support that, rather than endocytosis, the cellular uptake of the S4 13 -PV cell-penetrating peptide is a consequence of its direct translocation through cell membranes following conformational changes induced by peptide-membrane interactions.
Introduction
Cell-penetrating peptides (CPPs) have been shown to very efficiently cross eukaryotic cell membranes through a temperature-insensitive and energy-independent mechanism that does not involve membrane receptors or transporters. Interestingly, cell-penetrating peptides also have the remarkable ability to mediate the intracellular delivery of a wide variety of molecules of pharmacological interest, both in vitro and in vivo (for recent reviews, see [1] [2] [3] [4] [5] ).
Despite great variability in the amino acid sequence, CPPs are usually short peptide sequences rich in basic amino acids, in some cases exhibiting the ability to be arranged in amphipathic alpha-helices. The peptides derived from the HIV-1 Tat protein and from the homeodomain of the Antennapedia protein of Drosophila (Tat and Penetratin (pAntp) peptides, respectively) [6, 7] , as well as the synthetic Pep-1 peptide [8] are among the best-characterized cellpenetrating peptides.
Consistent with the capacity of CPPs and of their conjugates to enter into a wide variety of cell types from different tissues and organisms, the glycosaminoglycan (GAG) moieties of the ubiquitous cell surface heparan sulfate proteoglycans (HSPGs) have been identified as playing an important role in mediating electrostatic interactions of cell-penetrating peptides with biological membranes [9, 10] .
Despite the widespread use of cell-penetrating peptides for delivery purposes and the extensive research on the unusual ability of these peptides to traverse cell membranes and promote intracellular uptake of various cargo molecules, the mechanisms underlying the cellular uptake of CPPs are not completely elucidated. Recent reports attributing the cellular uptake and nuclear accumulation of some cell-penetrating peptides to an artifactual redistribution of membrane-associated peptide molecules and conjugates [11] [12] [13] , have motivated a re-evaluation of the mechanisms responsible for their cellular uptake. Interestingly, results from criterious re-evaluations of cellular uptake under experimental conditions that avoid artifactual observations, have implicated the involvement of well-characterized endocytic pathways, such as clathrin-mediated endocytosis [10] , caveolae-mediated endocytosis [14, 15] or macropinocytosis [16, 17] in the internalization of several peptides and their conjugates.
Given the conflicting results regarding the mechanisms on the cellular uptake of cell-penetrating peptides, we have previously characterized the cellular uptake of the S4 13 -PV karyophilic cell-penetrating peptide [18] . In the present manuscript, we review research results obtained in our laboratory on the interaction of S4 13 -PV peptide with cells and model membranes, aimed to understand the sequence of events underlying translocation of this peptide across biological membranes. The S4 13 -PV cell-penetrating peptide results from the combination of a 13 amino acid cell-penetrating sequence, derived from the Dermaseptin S4 peptide, with the SV40 large T antigen nuclear localization signal [19] . Table 1 compares the amino acid sequence of the S4 13 -PV peptide with those of cellpenetrating peptides commonly used for cargo delivery.
Collectively, the obtained data indicate that the cellular uptake of the S4 13 -PV peptide is a very efficient, non-toxic and dose-dependent process, which occurs mainly through a mechanism distinct from endocytosis, most likely involving the direct penetration of the peptide through cell membranes.
Comparative analysis of peptide uptake by mutant cells lacking heparan sulfate proteoglycans, as well as studies with model membranes, demonstrate that the presence of HSPGs or other negatively charged components on the surface of target membranes potentiates the extent of peptide-membrane interactions, which are mainly of electrostatic nature. As a consequence of these peptide-membrane interactions, the S4 13 -PV peptide becomes inserted into the lipid bilayer, which occurs concomitantly with significant conformational changes of the peptide that are consistent with an increase in its helical content. Comparative analysis using different peptides demonstrates that these conformational changes are dependent on the peptide sequence, providing clear evidence that the secondary structure acquired by the S4 13 -PV peptide upon its interaction with target membranes is intricately related to its capacity to translocate across cell membranes.
Materials and methods

Cells
HeLa cells (human epithelial cervical carcinoma) were maintained at 37°C, under 5% CO 2 , in Dulbecco Modified Eagle medium-high glucose (DMEM; Sigma, St. Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Biochrom KG, Berlin, Germany), and with 100 units penicillin and 100 μg streptomycin (Sigma) per ml.
CHO-K1 and pgs A-745 Chinese hamster ovary cell lines were grown in F-12 (Ham) Nutrient Mixture (Invitrogen, UK) supplemented with 10% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 μg/ml), 2 mM Lglutamine (Sigma), 10 mM HEPES (Sigma) and 14 mM sodium bicarbonate (Sigma).
Peptides
High purity (N95%) S4 13 -PV peptide (ALWKTLLKKVLKAPKKKRKVC), reverse NLS peptide (ALWKTLLKKVLKAVKRKKKPC) and scrambled peptide (KTLKVAKWLKKAKPLRKLVKC) were obtained from Thermo Electron (Thermo Electron GmbH, Germany). In the reverse NLS peptide, the sequence corresponding to the nuclear localization signal of the SV40 large T antigen (aa [14] [15] [16] [17] [18] [19] [20] is inverted; the scrambled peptide was generated based on the S4 13 -PV peptide sequence, so that the resulting peptide had the same amino acid composition and overall charge, but a distinct primary sequence. During synthesis, peptides were either fluorescently labeled with 5-(6)-tetramethylrhodamine (TAMRA), or modified with an acetyl group at the N-terminus, and further modified by introducing an amide group at the C-terminus. Freeze-dried peptides were reconstituted in high purity water.
Peptide concentration was determined by amino acid analysis and light absorption at 280 nm. Amino acid analysis was performed in a Beckman 6300 automatic analyzer, following acid hydrolysis of the peptide.
Peptide cellular uptake
For experiments on peptide uptake, 0.8 × 10 5 cells/well were seeded onto 12-well plates (flow cytometry) or 12-well plates containing 16 mm glass coverslips (confocal microscopy), 24 h prior to incubation with the peptide. The cells were then washed with phosphate-buffered saline (PBS) and incubated with 1.0 μM of either the S4 13 -PV peptide or scrambled peptide, in serum-free medium, for 30 min or 1 h, at 37°C.
Analysis of peptide internalization was performed by confocal laser scanning microscopy and flow cytometry. To avoid any possible artifactual observations caused by cell fixation, analysis of peptide uptake was performed always in live cells.
To address the effect of drugs that compromise different endocytic pathways on the uptake of the S4 13 -PV peptide, HeLa cells were washed with PBS and The effect of heparin on the cellular uptake of the S4 13 -PV peptide was also evaluated. For this purpose, HeLa cells were washed with PBS and then pretreated for 30 min, at 37°C, in serum-free DMEM, with 10 μg/ml heparin (sodium salt from bovine intestinal mucosa; Sigma), followed by incubation with the peptide in the presence of heparin, for 1 h, at 37°C, in serum-free DMEM. The concentration of heparin used in this study corresponds to a clear excess of negative charges with respect to the positive charges of the peptide, which allows to accurately mimic the interaction of the peptide with a cell surface rich in heparan sulfate proteoglycans.
The effect of the drugs that affect different endocytic pathways was confirmed, in parallel control experiments, by analyzing the cellular uptake of fluorescently labeled transferrin, a known marker of clathrin-mediated endocytosis, and lactosylceramide, a marker of raft/caveolae-dependent endocytosis (data not shown). No significant cytotoxicity was associated to the treatment of cells with any of the drugs used in this study (data not shown).
Flow cytometry analysis was performed in live cells, using a Becton Dickinson FACSCalibur flow cytometer. Data were obtained and analyzed using CellQuest software (BD Biosciences). Since flow cytometry analysis does not discriminate between membrane-associated and internalized peptide, after incubation with the different peptides, the cells were washed once with PBS and trypsinized (10 min, 37°C) to remove any surface-bound, non-internalized peptide, which could result in an overestimation of cellular uptake. The cells were then further washed, resuspended in PBS, and immediately analyzed. Live cells were gated by forward/side scattering from a total of 10000 events.
For analysis of the subcellular localization of the peptides by confocal microscopy, following peptide-cell incubation the cells were washed and mounted in PBS, and immediately visualized. Observations were performed, in live cells, using a Bio-Rad MRC 600 fluorescence confocal microscope equipped with an argon/krypton laser (Bio-Rad Laboratories, Inc.).
Liposome preparation
Large unilamellar vesicles (LUVs) were prepared by extrusion of multilamellar vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; Avanti Polar Lipids, AL), 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (POPG; Avanti), or mixtures of these two lipids at different molar ratios [(POPC:POPG (1:1) and POPC:POPG (4:1)].
Lipid solutions in chloroform were mixed at the desired molar ratios, and dried under vacuum, at room temperature, using a rotary evaporator. The dried lipid films were then hydrated with 1.0 ml high purity water, and the multilamellar vesicles obtained were briefly sonicated and extruded 21 times through two stacked polycarbonate filters (100 nm pore diameter) using a Liposofast device (Avestin, Toronto, Canada).
Total lipid concentrations of the resulting LUVs were determined by the Bartlett method [20] , and 10 mM stock solutions of the different liposome formulations were prepared.
Steady-state fluorescence spectroscopy
Steady-state fluorescence measurements were performed in a SPEX Fluorolog 2 spectrofluorometer, at room temperature, using 10 × 2 mm, or 5 × 5 mm quartz cuvettes.
Interaction of S4 13 -PV peptide with lipid vesicles of different compositions (LUVs) was assessed by following peptide intrinsic fluorescence upon sequential addition of small volumes of concentrated vesicle stock solutions to peptide samples, up to a lipid/peptide molar ratio of 40. Experiments were performed in 10 mM sodium phosphate buffer (pH 7.0), and concentration of S4 13 -PV peptide was 2.5 μM. Excitation wavelength was 280 nm and fluorescence emission was scanned from 300 to 400 nm.
All spectra were corrected for background contributions of buffer, and of different concentrations of vesicles. Spectra were not corrected for the photomultiplier wavelength dependence.
Partition coefficients
Partition coefficients (K p ) were determined based on the changes in the fluorescence intensity of the S4 13 -PV peptide observed in the presence of lipid vesicles of different compositions. The relationships and assumptions used to determine K p were previously described [21] , 
Quenching of tryptophan fluorescence
Quenching of tryptophan fluorescence by acrylamide was evaluated either in aqueous buffer, or in the presence of lipid vesicles, at the lipid/peptide molar ratio of 40. Under the different experimental conditions, the quenching constants (K SV ) for the S4 13 -PV peptide were determined by linear regression using the Stern-Volmer equation [23, 24] :
where F 0 and F are the fluorescence intensities of tryptophan emission in the absence and presence of the quencher, respectively, and [Q] is the molar concentration of the quencher in the sample. Emission spectra of the S4 13 -PV peptide (2.5 μM) were acquired as described previously, in the presence of different acrylamide concentrations (5-100 mM). Acrylamide was added from a 1.0 M aqueous stock solution. Spectra were corrected for background fluorescence of buffer, vesicles and different concentrations of acrylamide, as well as for the inner filter effect.
Circular dichroism spectroscopy
Circular dichroism (CD) spectra were acquired in a Jasco J-715 spectropolarimeter using 1.0 mm quartz cuvettes. Experiments were performed at 15°C, in 10 mM sodium phosphate buffer (pH 7.0), or in the same buffer containing lipid vesicles, at different lipid/peptide molar ratios. Five spectra were collected and averaged for each sample. Peptide concentrations ranged from 5 to 50 μM, and maximal lipid concentration was 0.2 mM. All spectra were corrected for background contributions of buffers and lipid vesicles, and smoothed using the Jasco J-715 noise reduction software.
To facilitate interpretation of the circular dichroism spectra obtained under the different experimental conditions, the relative contribution of three secondary structure elements (α-helix, β-structure and random coil) to the overall structure of the peptide was estimated by computer fitting of the CD spectra according to the algorithm convex constraint analysis (CCA).
Results
Cellular uptake of S4 13 -PV cell-penetrating peptide
To evaluate the efficiency of S4 13 -PV peptide internalization, flow cytometry analysis of HeLa cells exposed to increasing concentrations of rhodamine-labeled peptide was performed. Enzymatic digestion of membrane-associated, non-internalized peptide prior to flow cytometry analysis ensured an accurate evaluation of peptide uptake.
Analysis of the flow cytometry results revealed that the number of cells containing the peptide and the amount of peptide internalized by cells markedly increased with peptide concentration, within the concentration range examined (Fig. 1a) .
Although the S4 13 -PV peptide and its derivative scrambled peptide have similar physico-chemical properties (peptide length, mass and charge), the extent of cellular uptake of the S4 13 -PV peptide was significantly higher than that observed for the scrambled peptide (Fig. 1b) . Additionally, the two peptides presented clearly distinct subcellular localizations: the S4 13 -PV peptide was distributed throughout the cytoplasm and nucleus of cells, accumulating in nucleoli, whereas the scrambled peptide presented a punctate cytoplasmic distribution, which is consistent with its uptake through an endocytic mechanism (Fig. 1b) .
Additional studies aimed at evaluating the effect of the peptides on membrane integrity revealed that incubation of HeLa cells with the S4 13 -PVor scrambled peptides up to 2.0 μM concentration does not result in significant cytotoxicity, as assessed by propidium iodide exclusion by viable cells ( [18] and data not shown).
The different cellular uptake of the S4 13 -PV and scrambled peptides highlights the relevance of peptide sequence in dictating the mechanism and efficiency of peptide uptake, which ultimately determine its intracellular fate.
Mechanisms of peptide cellular uptake
In face of recent reports demonstrating that endocytosis is responsible for the cellular uptake of several cell-penetrating peptides, the involvement of endocytosis in the cellular uptake of the S4 13 -PV peptide was carefully evaluated.
Endocytosis is a very complex cellular process that may occur through several distinct mechanisms, usually divided into two broad categories: phagocytosis, a process restricted to specialized mammalian cells, and pinocytosis, which occurs in all mammalian cells and encompasses macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, Fig. 1 . Cellular uptake of S4 13 -PV cell-penetrating peptide. (a) Effect of the S4 13 -PV peptide dose on its cellular uptake. HeLa cells were incubated with increasing concentrations of rhodamine-labeled S4 13 -PV peptide, at 37°C, for 1 h. Extent of peptide uptake was analyzed by flow cytometry following cell treatment with trypsin, to remove non-internalized, surface-bound peptide. (b) Effect of peptide sequence on peptide uptake. HeLa cells were incubated with 1.0 μM of rhodamine-labeled S4 13 -PV or scrambled peptides, at 37°C, for 30 min. Cells were washed and immediately observed by confocal fluorescence microscopy. All experiments were performed using live cells.
as well as other less characterized clathrin-and caveolaeindependent endocytic pathways [25, 26] .
To investigate the involvement of the different endocytic pathways in the cellular uptake of the S4 13 -PV peptide, the effect of chlorpromazine (a known inhibitor of clathrinmediated endocytosis), of MβCD and nystatin (which deplete or sequester membrane cholesterol, inhibiting endocytic pathways dependent on lipid-rafts such as macropinocytosis, caveolae-and clathrin-mediated endocytosis [26] ), of cytochalasin D (an inhibitor of F-actin elongation required for phagocytosis, macropinocytosis and caveolar endocytosis [27] ) and of amiloride (which specifically blocks the Na + /H + exchange required for macropinocytosis [28] ), was evaluated.
As can be observed in Fig. 2 , only cytochalasin D had a significant inhibitory effect on the extent of cellular uptake of the S4 13 -PV peptide, which might support a role for endocytosis in the internalization of this peptide. However, the lack of inhibition observed for all the other tested drugs, which also compromise the endocytic pathways that are affected by cytochalasin D, consistently excluded the involvement of endocytosis in the cellular uptake of the S4 13 -PV peptide, at a peptide concentration that results in its efficient cellular uptake by the majority of cells (1.0 μM).
Role of heparan sulfate proteoglycans (HSPGs) in peptide uptake
As a first approach to address the involvement of cell surface heparan sulfate proteoglycans in the cellular uptake of the S4 13 -PV peptide, the competitive effect of heparin on this process was evaluated. Heparin mimics the glycosaminoglycan moieties of proteoglycans ubiquitously present at cell surfaces, and has been shown to bind Tat peptide very efficiently [29] and to impair the cellular uptake of Tat fusion proteins [9, 15, 17, 30] .
Results from these experiments demonstrated that heparin completely blocks the cellular uptake of the S4 13 -PV peptide (Fig. 2) , strongly suggesting that cell surface proteoglycans play an important role in peptide-cell interaction.
To accurately evaluate the relevance of cell surface heparan sulfate proteoglycans to the interaction of the S4 13 -PV peptide with biological membranes, comparative uptake studies were performed in CHO-K1 and pgs A-745 cell lines. pgs A-745 is a mutant cell line derived from CHO-K1 that is unable to synthesize proteoglycans, since it is defective in xylosyltransferase I, an enzyme involved in the early steps of glycosaminoglycan biosynthesis [31, 32] .
Flow cytometry analysis of the uptake of the S4 13 -PV peptide by these two cell lines demonstrated that peptide uptake was more extensive in cells containing heparan sulfate proteoglycans (CHO-K1; Fig. 3a) , when compared to that in mutant cells lacking proteoglycans (pgs A-745; Fig. 3b) . Nonetheless, the effect of HSPGs on facilitating the cellular uptake of S4 13 -PV peptide was highly dependent on peptide concentration: at low peptide concentrations, peptide uptake by cells lacking proteoglycans (pgs A-745) was approximately 10-fold lower than that by cells containing proteoglycans (CHO-K1), whereas, for higher peptide concentrations, smaller differences were observed (Fig. 3) .
Overall, the results from this comparative analysis reinforce the relevance of HSPGs to the efficient cellular uptake of the S4 13 -PV peptide, although the presence of these membrane components at cell surface is not mandatory.
Interaction of S4 13 -PV peptide with model membranes
To characterize the interaction of the S4 13 -PV peptide with membranes, a detailed analysis addressing the effect of charge density of the target membrane and of lipid/peptide ratio on the fluorescence emission spectra of the S4 13 -PV peptide was performed.
Interestingly, the emission spectra of the S4 13 -PV peptide remained unchanged in the presence of neutral vesicles composed of POPC, whereas upon interaction with negatively charged vesicles, clear changes in the wavelength of maximal emission of the S4 13 -PV peptide towards shorter wavelengths (blue-shift) were observed, concomitantly with significant increases in fluorescence intensity (Fig. 4) .
Partition coefficients (K p ), determined from the changes of peptide intrinsic fluorescence intensity observed in the presence of the different lipid vesicles, clearly indicate that the extent of peptide-membrane interaction is dependent on the surface density of negatively charged components of the target membrane ( Table 2) .
The shift of peptide maximal fluorescence towards shorter wavelengths (blue-shift) observed in the presence of the different negatively charged vesicles clearly indicates that, Fig. 2 . Effect of different drugs on the cellular uptake of S4 13 -PV peptide. Flow cytometry quantification of the extent of cellular uptake of S4 13 -PV peptide in the presence of drugs that inhibit different endocytic pathways, or heparin. HeLa cells pre-treated with the different drugs for 30 min, at 37°C, were incubated, in the presence of the drugs, with fluorescently-labeled S4 13 -PV peptide (1.0 μM, 1 h), at the same temperature, as described in Materials and methods. Flow cytometry analysis was performed in live cells, following treatment with trypsin, to remove non-internalized, surface-bound peptide. Chlorpromazine (CHP) inhibits clathrin-mediated endocytosis, MβCD and nystatin inhibit endocytic pathways dependent on lipid-rafts by depleting or sequestering membrane cholesterol, cytochalasin D (cytD) inhibits F-actin elongation required for phagocytosis, macropinocytosis, caveolar endocytosis, as well as other cellular processes, and amiloride blocks the Na + /H + exchange required for macropinocytosis. Heparin mimics glycosaminoglycan moieties of cell surface heparan sulphate proteoglycans.
following its interaction with the vesicles, the S4 13 -PV peptide becomes localized in a highly hydrophobic environment. Interestingly, the magnitude of the blue-shift of maximal fluorescence emission of the S4 13 -PV peptide induced by the negatively charged vesicles increased with the charge density of target membranes (POPC:POPG (4:1) b POPC:POPG (1:1) b POPG), as well as with lipid/peptide ratio ( Fig. 4; Table 2 ). As expected, with increasing lipid/peptide ratios, the difference between the magnitudes of the blue-shifts induced by the different negatively charged vesicles was progressively less pronounced, the shifts being comparable at lipid/peptide ratios of 40, or higher ( Fig. 4b; Table 2 ).
In agreement with the lack of interaction between the S4 13 -PV peptide and neutral membranes, quenching values of intrinsic fluorescence of the S4 13 -PV peptide by acrylamide in the presence of lipid vesicles composed of POPC were comparable to those of the peptide in buffer (as evaluated by the corresponding K SV ; Table 2 ), indicating that the S4 13 -PV peptide remains completely exposed to the aqueous environment in the presence of these vesicles. Conversely, following interaction of the S4 13 -PV with the different negatively charged vesicles, a significant decrease in the efficiencies of fluorescence quenching by acrylamide were observed, regardless of the density of negatively charged phospholipids in the target membranes (K SV ; Table 2 ).
Since the Stern-Volmer constants (K SV ) in Table 2 , are the product of the bimolecular quenching rate constant times the fluorescence lifetime, and the quantum yields and lifetimes increase upon interaction of the peptide with the membranes, the significant decrease of K SV observed in the presence of negatively charged membranes are a consequence of the shielding of the tryptophan to the aqueous environment, and thereby to the acrylamide quencher.
These results are in agreement with those described to above regarding the spectral changes of the S4 13 -PV peptide, which collectively demonstrate that the S4 13 -PV peptide, or at least the region of the peptide that contains the tryptophan residue, becomes less exposed to the aqueous environment, most likely buried into the lipid bilayer, as a consequence of its interaction with negatively charged membranes.
S4 13 -PV peptide conformational changes induced by target membranes
To determine whether the interaction of the S4 13 -PV peptide with membranes would result in changes of peptide conformation, circular dichroism experiments were performed in the presence of lipid vesicles of different compositions (neutral POPC vesicles, and negatively charged POPC:POPG (1:1) or POPG vesicles).
Analysis of circular dichroism spectra of the S4 13 -PV peptide in buffer clearly demonstrated that, when free in aqueous solution, the peptide is completely unstructured (Fig.  5) . Interestingly, the CD spectra of the S4 13 -PV peptide in the presence of vesicles composed of POPC was virtually indistinguishable from that obtained in buffer, demonstrating that no peptide conformational changes are induced by neutral membranes, even at high lipid/peptide ratios (Fig. 5) .
In contrast, prominent changes in the secondary structure of the S4 13 -PV peptide were observed in the presence of vesicles containing negatively charged phospholipids (Fig. 5) . In agreement with the changes in the intrinsic fluorescence of the S4 13 -PV peptide observed previously, the extent of peptide conformational changes induced by the different vesicles was highly dependent on membrane charge density (compare the results obtained in the presence of vesicles composed of POPG or POPC:POPG (1:1) at a lipid/peptide ratio of 4), as well as on the lipid/peptide ratio (exemplified by the peptide conformational changes induced by POPC:POPG (1:1) vesicles at lipid/ peptide ratios of 4 and 8). Analysis of the obtained CD spectra indicates that the changes in peptide conformation induced by the different negatively charged vesicles are consistent with an increase in the contribution of an alpha-helical structural component, and in some cases also of a beta structural component.
To elucidate whether the S4 13 -PV peptide secondary structure induced by the negatively charged membranes is a consequence of specific peptide-membrane interactions, or rather the outcome of non-specific interactions of electrostatic nature, and to analyze the relevance of the two components of the S4 13 -PV fusion peptide to this process, parallel circular dichroism experiments were performed using the reverse NLS and scrambled peptides.
Similarly to what was previously observed for the S4 13 -PV peptide, analysis of the CD spectra of the reverse NLS and scrambled peptides clearly showed that these peptides are completely unstructured in aqueous buffer (Fig. 6) . Nonetheless, the conformational changes of the scrambled peptide, induced upon its interaction with negatively charged membranes composed of POPG, were significantly less pronounced than those observed for the S4 13 -PV and reverse NLS peptides, and no increase of an alpha-helical structural component was detected (Fig. 6) .
Given the similar physico-chemical properties of the S4 13 -PV, reverse NLS and scrambled peptides (peptide length, mass Fig. 5 . Circular dichroism analysis of conformational changes of S4 13 -PV peptide in the presence of model membranes. Circular dichroism spectra of S4 13 -PV peptide were acquired in sodium phosphate buffer, pH 7.0, or in the presence of neutral target membranes composed of POPC, or negatively charged vesicles composed of POPC:POPG (1:1), or POPG, at the indicated lipid/ peptide ratios, as described in Materials and methods. Table 2 Biophysical characterization of the interaction of S4 13 -PV cell-penetrating peptide with target membranes of different phospholipid composition and charge), and the identical propensities of these peptides to form alpha-helical structures, as evaluated by CD experiments performed in trifluoroethanol (TFE), an apolar, "membrane-mimicking" solvent (data not shown), the distinct behavior of the peptides observed in the presence of negatively charged vesicles clearly demonstrates that the conformational changes induced by target membranes are highly dependent on peptide sequence. Moreover, these findings demonstrate that the sequence derived from the Dermaseptin S4 peptide, which corresponds to aa 1-13 of the S4 13 -PV and reverse NLS peptides, is required for the formation of a helical structure.
Discussion
Accumulated reports demonstrating that the cellular uptake of some cell-penetrating peptides occurs through endocytosis, or is a consequence of artifacts caused by cell fixation, prompted the re-evaluation of the mechanism involved in the cellular uptake of the Dermaseptin-derived S4 13 -PV cellpenetrating peptide.
In this context, the possible involvement of endocytosis in the cellular uptake of the S4 13 -PV peptide was investigated by analyzing the extent of peptide uptake in the presence of drugs that selectively compromise different endocytic pathways. Results demonstrating that the uptake of the S4 13 -PV peptide occurs through a very efficient, non-toxic and dose dependent mechanism, together with the observations that, among all the tested drugs, only cytochalasin D had an inhibitory effect on the cellular uptake of the S4 13 -PV peptide, excluded the involvement of endocytosis as the mechanism responsible for the efficient cellular uptake of the S4 13 -PV peptide. Additional observations showing that cellular uptake of the S4 13 -PV peptide was not inhibited upon cell treatment with metabolic inhibitors that non-specifically block all endocytic pathways (sodium azide, sodium fluoride, antimycin A; unpublished observations), as well as the diffuse rather than punctated intracellular distribution of the peptide, reinforce the lack of involvement of endocytosis in the cellular uptake of this peptide.
Although the results from experiments performed at lower peptide concentrations (0.2 μM and 0.4 μM) demonstrated the involvement of the clathrin-mediated pathway of endocytosis in the cellular uptake of the S4 13 -PV peptide [18] , it should be emphasized that at peptide concentrations leading to efficient uptake of the peptide by the majority of cells (1.0 μM), the involvement of an endocytosis-independent mechanism of uptake is clearly prevalent.
The dramatic inhibition of cellular uptake of the S4 13 -PV peptide by heparin, which mimics GAG moieties of heparan sulfate proteoglycans ubiquitously present at cell surfaces, strongly suggests that the interactions between the positively charged peptide and highly negatively charged membrane components play an important role in the overall process of cellular uptake of the peptide.
More interestingly, comparative analysis of peptide uptake by normal and genetically modified cells that are deficient in proteoglycan biosynthesis clearly demonstrated that heparan sulfate proteoglycans potentiate the cellular uptake of the S4 13 -PV peptide. This effect is particularly relevant for low peptide concentrations, most likely because binding of the peptide to cell membranes is not a limiting step to the cellular uptake at high peptide concentrations. Nonetheless, and in contrast with previous reports showing that heparan sulfate proteoglycans are absolutely required for the cellular uptake of full length tat and tat-fusion proteins [9, 10, 33] , the presence of HSPGs at cell surface is not mandatory for the cellular uptake of the S4 13 -PV peptide.
Moreover, the results obtained indicate that binding of the S4 13 -PV peptide to cell membranes, which is facilitated by interaction with cell surface HSPGs, can either result in the endocytic uptake of the peptide (as discussed above for experiments performed at low S4 13 -PV peptide concentrations), or evoke conformational changes in the peptide, which occur concomitantly with its insertion into the membrane leading to its efficient uptake by the majority of cells.
The data demonstrating that the main mechanism responsible for the cellular uptake of the S4 13 -PV cell-penetrating peptide is distinct from endocytosis and is facilitated by the presence of negatively charged proteoglycans at cell surface indicate that the membrane translocation of the S4 13 -PV cell-penetrating peptide results from its direct interaction with biological membranes. Aiming at gaining insights into the molecular mechanisms underlying the translocation of the S4 13 -PV peptide across biological membranes, a detailed characterization of the interaction of the S4 13 -PV peptide with model membranes was performed. In agreement with the role of proteoglycans in facilitating peptide uptake, analysis of the interaction of the S4 13 -PV peptide with target membranes of different phospholipid compositions clearly demonstrated that the extent of peptidemembrane interactions is dependent on the relative amount of negatively charged membrane components on the target membrane. Although these results indicate that the interactions established between the S4 13 -PV peptide and target membranes are essentially of electrostatic nature, the interaction of the peptide with cell surface proteoglycans may involve some structural recognition.
As a consequence of the interaction of the S4 13 -PV peptide with negatively charged target membranes, significant changes in the intrinsic fluorescence spectra of the peptide were detected, namely an increase in the fluorescence intensity and a shift of the wavelength of maximal emission towards shorter wavelengths (blue-shift). These spectral changes, which are indicative of an increase in the hydrophobicity of the peptide environment, were dependent both on the density of negatively charged phospholipids in the target membrane and on the lipid/ peptide ratio. Remarkably, the magnitude of the blue-shifts induced upon interaction of the S4 13 -PV peptide with negatively charged membranes, at the lipid/peptide ratio of 40 (30 nm in the case of POPG vesicles), is extremely high, specially when compared to those previously reported for other CPPs, such as the Penetratin, Transportan or Pep-1 peptides, for which lower shifts were observed [34] [35] [36] [37] .
In agreement with these changes of peptide intrinsic fluorescence, the Stern-Volmer quenching constants (K SV ) calculated in the presence of the different negatively charged vesicles undoubtedly demonstrated that the S4 13 -PV peptide, or at least the region of the peptide that contains the tryptophan residue, becomes localized into an extremely hydrophobic environment as a consequence of its interaction with negatively charged membranes, most likely inserted into the lipid bilayer.
Concomitantly with the spectral changes described previously, circular dichroism analysis revealed that the interaction of the S4 13 -PV peptide with the negatively charged vesicles used in this study also induced significant peptide conformational changes, consistent with an increase in the helical content of the peptide, whose extent was dependent on the density of negatively charged phospholipids in the target membrane, as well as on the lipid/peptide ratio. The similar dependences observed for the magnitude of the spectral changes and the extent of peptide conformational changes strongly suggest that the latter are intricately associated to the insertion of the S4 13 -PV peptide into target membranes, and presumably to its ability to translocate across biological membranes.
In this context, it is noteworthy that significant differences were observed between the conformational changes of the S4 13 -PV and reverse NLS peptides, induced upon their interaction with negatively charged target membranes, and those of the scrambled peptide. This distinct behavior highlights the importance of the sequence derived from the Dermaseptin S4 peptide to the formation of the alpha-helical structure resulting from the interaction of the S4 13 -PV peptide with negatively charged membranes. Moreover, these data strongly indicate that such conformational changes are of critical importance for the increased capacity exhibited by the S4 13 -PV peptide to translocate across biological membranes, as compared to the scrambled peptide. Interestingly, in contrast to the scrambled peptide, the amino acids 1-13 of the S4 13 -PV and reverse NLS peptides, which were originally derived from the Dermaseptin peptide, have the capacity to be arranged as an amphipathic α-helix (Fig. 7) . Although this feature is not a requirement for peptide translocation across membranes, the importance of these structural motifs in inducing local membrane destabilization, which can be crucial for peptide translocation, should not be neglected.
Overall, the results reviewed in the present study demonstrate that the main mechanism involved in the cellular uptake of the S4 13 -PV peptide, which is distinct from endocytosis, can be rationalized in several distinct steps. The process is initiated by the binding of the S4 13 -PV cell-penetrating peptide to membranes, as a consequence of electrostatic interactions established with negatively charged membrane components, such as the highly negatively charged cell surface heparan sulfate proteoglycans, in the case of cell membranes. As a consequence of peptide-membrane interactions that occur upon binding to target membranes, the S4 13 -PV peptide becomes inserted into the lipid bilayer, which occurs concomitantly with significant conformational changes of the peptide that result in the formation of an amphipathic α-helix. Whether these conformational changes constitute a requirement for the insertion of the S4 13 -PV peptide into the lipid bilayer, or a consequence of this process, is not clear. In any case, the translocation of the peptide to the intracellular milieu is, most likely, a consequence of a transient and confined membrane destabilization induced by the amphipathic α-helix that is formed upon peptide-membrane interaction. Based on recent reports demonstrating that the transbilayer membrane potential that exists across cell membranes (negative inside) is required Fig. 7 . Helical plot representation of the S4 13 -PV cell-penetrating peptide. Only the amino acids 1-13, which are derived from the Dermaseptin peptide, are plotted. Most likely, the sequence corresponding to the NLS of SV40 remains unstructured due to repulsion forces between positively charged residues. Hydrophilic amino acids are shown in black.
for the cellular uptake of several cell-penetrating peptides [38] [39] [40] , the possibility that the membrane potential also acts as a driving force for the membrane translocation of the S4 13 -PV peptide should not be excluded.
Studies are currently in progress in our laboratory aiming at evaluating the potential of the S4 13 -PV cell-penetrating peptide to mediate the intracellular delivery of molecules of pharmacological interest, including drugs, proteins and nucleic acids.
